IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.

Authors :: Wang CQF
Suárez-Fariñas M
Nograles KE
Mimoso CA
Shrom D
Dow ER
Heffernan MP
Hoffman RW
Krueger JG
Source :: The Journal of investigative dermatology [J Invest Dermatol] 2014 Dec; Vol. 134 (12), pp. 2990-2993. Date of Electronic Publication: 2014 Jul 07.
Publication Year :: 2014

Subjects :: Antibodies, Monoclonal therapeutic use
Cells, Cultured
Dose-Response Relationship, Drug
Humans
Infusions, Intravenous
Injections, Subcutaneous
Interleukin-17 administration & dosage
Interleukin-17 immunology
Monocytes pathology
Receptors, Chemokine metabolism
Signal Transduction drug effects
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Cytokines metabolism
Interleukin-17 pharmacology
Monocytes drug effects
Monocytes metabolism
Psoriasis drug therapy
Psoriasis metabolism

Full Text Access

Tools